GlassScriptPhysician profile
Demaree L Trammel
NPI 1255333068
$455.86
in general payments reported to CMS, 2019-2025
9 companies · $90.64 in 2025
The $90.64 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.90 · 2023: $32.34 · 2024: $313 · 2025: $90.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $435.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $215.05 | 2024-2025 | Austedo Xr, Austedo Xr |
| Lundbeck LLC | $48.34 | 2024 | Rexulti |
| Tris Pharma INC | $44.16 | 2024 | Dyanavel Xr |
| Corium, LLC | $40.74 | 2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $38.14 | 2023-2024 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.93 | 2024 | Caplyta |
| Sunovion Pharmaceuticals INC. | $19.90 | 2019 | |
| Bausch Health US, LLC | $15.58 | 2024 | Aplenzin, Wellbutrin |
| Neurocrine Biosciences, INC. | $14.02 | 2023 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Demaree Trammel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.